Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Despite reporting a Phase 3 win this summer, Pfizer terminated its hemophilia A gene therapy pact with Sangamo Therapeutics in a move that cast a pall on the ...